Gluconate Zinc Market Intelligence Report (May 27, 2026)

I. Market Price Dynamics
- Raw Material Prices: As of May 26, 2026, Wuhan Hengjiu Chemical Co., Ltd. quoted RMB 4,500 per metric ton (tax-inclusive) for 97% purity zinc gluconate, delivered to Hubei Province. Packaging specifications were not explicitly stated, but the product complies with food and feed additive standards. This price has remained stable since May 18, reflecting short-term supply-demand equilibrium.
- Active Pharmaceutical Ingredient (API) Prices: In 2025, the average ex-factory price for industrial-grade zinc gluconate (≥99.0%) was RMB 82.4 per kilogram; for pharmaceutical-grade material (meeting the requirements of the *Chinese Pharmacopoeia* 2020 Edition), the average was RMB 136.8 per kilogram. Year-on-year prices remained unchanged, indicating manageable upstream cost pass-through pressure.

II. Terminal Market Demand Analysis
1. OTC Pharmaceutical Market
- In Q1 2026, sales of zinc gluconate oral solutions increased by 70% year-on-year, making it a representative 'dual-high' product (large scale and high growth rate) within the vitamin and mineral supplement category. Growth was primarily driven by seasonal household health preparedness and heightened consumer awareness of preventive health management.
- Zinc gluconate–calcium oral solution—the largest-selling formulation—generated over RMB 1.1 billion in Q1 2026, representing a 20% year-on-year increase, underscoring the resilience of leading products.

2. Segmented Market Expansion
- Pediatric Nutrition: Zinc gluconate formulations account for approximately 65% of the pediatric zinc supplementation drug market. This share is expected to further increase with new drug development and expanded clinical applications.
- Adult Nutrition: High-margin dosage forms containing zinc gluconate—such as multivitamin gummies and chewable tablets—accounted for 38.2% of sales in infant, toddler, and adolescent markets in 2026. Their average ex-factory unit price is 2.3 times higher than that of conventional tablets, lifting the overall market valuation benchmark.
- Geriatric Nutrition: Nestlé’s Jianshan Youxuan senior nutrition supplements launched a zinc-fortified version, achieving over RMB 12 million in retail sales within six months of launch—highlighting the growing demand for zinc among the aging population ('silver economy').

3. Export Market
- In 2025, export revenue for zinc gluconate API reached RMB 317 million, up 12.9% year-on-year, with primary destinations being Southeast Asia, the Middle East, and Africa. Imports by Saudi Arabia, Indonesia, and Nigeria collectively accounted for 43.6% of total exports. Regulatory incentives in these countries—including inclusion of zinc gluconate in their over-the-counter (OTC) nutritional supplement 'white lists'—are projected to take full effect in 2026, forming a second growth curve.

III. Industry Competitive Landscape
1. Rising Market Concentration
- The CR5 (combined market share of the top five enterprises) stood at 68.3% in 2025, with Hunan Wanar Pharmaceutical Co., Ltd. leading at 22.1%. Its newly commissioned intelligent production line—with an annual capacity of 3,000 metric tons—reduced per-unit manufacturing costs by 18.7%, conferring significant cost advantages.
- The CR5 is projected to rise to 57.1% in 2026, signaling accelerated industry consolidation and intensified resource concentration toward leading firms.

2. Corporate Strategic Layouts
- Companies including Hunan Wanar Pharmaceutical, Zhejiang Asia-Pacific Pharmaceutical, and Guangdong Dongyang Light Pharmaceutical have achieved vertical integration across API and finished-dosage manufacturing. In 2025, this integrated business segment achieved an average gross margin of 62.4%, markedly exceeding the industry average (41.7%), with excellent cash flow quality.
- China Resources Sanjiu has launched a county-level healthcare zinc supplementation promotion program, covering 1,800 county hospitals—deepening channel penetration and reinforcing competitive advantage.

IV. Policy & Regulatory Impact
1. Policy Support
- The 2025 Silver-Age Health Nutrition Intervention Pilot Program now covers 127 prefecture-level cities nationwide, expected to generate approximately RMB 82 million in additional annual procurement demand for zinc gluconate formulations.
- Export-related policy tailwinds—including OTC white-list adoption in Southeast Asia and the Middle East—continue to drive export growth.

2. Regulatory Risks
- The National Center for Food Safety Risk Assessment has initiated a research project titled 'Revision Study on Zinc Content Limits in Nutritional Supplements'. If the revised standard—scheduled for 2026—lowers the recommended maximum daily intake from 40 mg to 30 mg, high-dose combination products may face short-term pressure. However, such revision would also accelerate the exit of low-quality producers, strengthening pricing power for compliant industry leaders.

V. Market Outlook & Trends
1. Short-Term Forecast (2026)
- Total market size is projected to reach RMB 1.379 billion, representing 7.2% year-on-year growth—slightly lower than 2025’s pace, mainly due to base-effect expansion and stricter environmental inspections prompting some small-to-medium manufacturers to exit.
- Raw material prices are expected to remain stable: industrial-grade average at RMB 82–83/kg; pharmaceutical-grade average at RMB 136–137/kg—cost pass-through pressure remains manageable.

2. Long-Term Trends (2026–2030)
- Technological Upgrading: Continuous-flow crystallization processes will reduce impurity levels to ≤0.05%, enhancing product competitiveness.
- Application Expansion: Transition beyond pharmaceuticals into food, dietary supplements, and cosmetics sectors; green manufacturing will become mandatory.
- Internationalization: Export market share is set to grow, with Southeast Asia, the Middle East, and Africa emerging as key growth engines.
- Increased Concentration: CR5 is expected to exceed 60%, as leading enterprises pursue M&A and restructuring to achieve economies of scale.

3. Investment Opportunities
- High-Certainty Sector: Combines robust pharmaceutical attributes with strong consumer appeal, supported by well-established clinical evidence and reliable terminal sales performance.
- Differentiated Competition: Priority focus areas include high-margin dosage forms (e.g., gummies, chewables), county-level healthcare distribution channels, and export markets.
- Risk Mitigation: Monitor developments regarding the zinc content limit revision; prioritize enterprises with high proportions of compliant production capacity.